OPKO Health Valuation
Is OPK * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of OPK * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: OPK * (MX$32.3) is trading below our estimate of fair value (MX$158.51)
Significantly Below Fair Value: OPK * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OPK *?
Key metric: As OPK * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is OPK *'s PS Ratio? | |
|---|---|
| PS Ratio | 1.6x |
| Sales | US$711.41m |
| Market Cap | US$1.08b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.7x |
| Enterprise Value/EBITDA | -5.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does OPK *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.6x | ||
MEDICA B Médica Sur. de | 0.8x | 5.5% | Mex$3.3b |
AMN AMN Healthcare Services | 0.3x | -5.4% | US$983.8m |
300244 Dian Diagnostics GroupLtd | 0.6x | 8.2% | CN¥7.8b |
4544 H.U. Group Holdings | 0.6x | 4.0% | JP¥138.0b |
OPK * OPKO Health | 1.6x | 6.8% | Mex$1.1b |
Price-To-Sales vs Peers: OPK * is expensive based on its Price-To-Sales Ratio (1.6x) compared to the peer average (0.6x).
Price to Sales Ratio vs Industry
How does OPK *'s PS Ratio compare vs other companies in the South American Healthcare Industry?
| 3 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: OPK * is expensive based on its Price-To-Sales Ratio (1.6x) compared to the South American Healthcare industry average (0.8x).
Price to Sales Ratio vs Fair Ratio
What is OPK *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate OPK *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | Mex$81.27 0% | 56.8% | Mex$174.51 | Mex$41.06 | n/a | 6 |
| Nov ’25 | n/a | Mex$74.55 0% | 56.8% | Mex$160.09 | Mex$37.67 | n/a | 6 |
| Oct ’25 | n/a | Mex$74.55 0% | 56.8% | Mex$160.09 | Mex$37.67 | n/a | 6 |
| Sep ’25 | n/a | Mex$74.55 0% | 56.8% | Mex$160.09 | Mex$37.67 | n/a | 6 |
| Aug ’25 | n/a | Mex$69.67 0% | 61.5% | Mex$154.49 | Mex$27.26 | n/a | 6 |
| Jul ’25 | n/a | Mex$71.82 0% | 53.8% | Mex$143.63 | Mex$25.35 | n/a | 6 |
| Jun ’25 | n/a | Mex$71.82 0% | 53.8% | Mex$143.63 | Mex$25.35 | n/a | 6 |
| May ’25 | n/a | Mex$70.68 0% | 53.8% | Mex$141.37 | Mex$24.95 | n/a | 6 |
| Apr ’25 | n/a | Mex$70.68 0% | 53.8% | Mex$141.37 | Mex$24.95 | n/a | 6 |
| Mar ’25 | Mex$17.00 | Mex$72.67 +327.5% | 53.8% | Mex$145.33 | Mex$25.65 | n/a | 6 |
| Feb ’25 | n/a | Mex$73.13 0% | 50.6% | Mex$143.44 | Mex$33.75 | n/a | 6 |
| Jan ’25 | n/a | Mex$77.28 0% | 48.2% | Mex$148.73 | Mex$35.00 | n/a | 6 |
| Dec ’24 | Mex$25.33 | Mex$77.28 +205.1% | 48.2% | Mex$148.73 | Mex$35.00 | n/a | 6 |
| Nov ’24 | n/a | Mex$76.64 0% | 48.0% | Mex$145.31 | Mex$34.19 | n/a | 6 |
| Oct ’24 | n/a | Mex$76.64 0% | 48.0% | Mex$145.31 | Mex$34.19 | n/a | 6 |
| Sep ’24 | n/a | Mex$76.64 0% | 48.0% | Mex$145.31 | Mex$34.19 | n/a | 6 |
| Aug ’24 | Mex$30.00 | Mex$73.87 +146.2% | 49.7% | Mex$145.45 | Mex$34.22 | n/a | 6 |
| Jul ’24 | Mex$30.00 | Mex$73.87 +146.2% | 49.7% | Mex$145.45 | Mex$34.22 | n/a | 6 |
| Jun ’24 | n/a | Mex$84.99 0% | 43.0% | Mex$151.12 | Mex$53.34 | n/a | 5 |
| May ’24 | n/a | Mex$88.89 0% | 43.0% | Mex$155.78 | Mex$54.98 | n/a | 5 |
| Apr ’24 | Mex$25.00 | Mex$88.89 +255.6% | 43.0% | Mex$155.78 | Mex$54.98 | n/a | 5 |
| Mar ’24 | Mex$22.00 | Mex$88.75 +303.4% | 43.0% | Mex$155.54 | Mex$54.90 | Mex$17.00 | 5 |
| Feb ’24 | n/a | Mex$97.80 0% | 40.5% | Mex$167.93 | Mex$59.27 | n/a | 5 |
| Jan ’24 | n/a | Mex$97.80 0% | 40.5% | Mex$167.93 | Mex$59.27 | n/a | 5 |
| Dec ’23 | n/a | Mex$106.48 0% | 36.0% | Mex$166.45 | Mex$68.54 | Mex$25.33 | 4 |
| Nov ’23 | n/a | Mex$115.20 0% | 30.7% | Mex$172.16 | Mex$81.02 | n/a | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.